Ketamine Dosage for Depression
For treatment-resistant major depressive disorder (MDD), intravenous ketamine should be administered at 0.5 mg/kg infused over 40 minutes, with intranasal esketamine dosed at 56-84 mg twice weekly as an alternative option. 1
Patient Selection Criteria
Ketamine or esketamine should be reserved for patients who have failed at least 2 adequate trials of antidepressant medications—not as first-line therapy. 1 This represents a significant shift from the 2016 VA/DoD guideline that recommended against ketamine use outside research settings. 1
Intravenous Ketamine Dosing
Standard Protocol
- Dose: 0.5 mg/kg based on actual body weight 2, 3
- Administration: Infuse slowly over 40-60 minutes (not the rapid bolus used in anesthesia) 4
- Frequency: Single dose initially, with potential for repeated administration to maintain gains 1
- Duration of effect: Improvements persist for 3-7 days when used as adjunctive therapy with ongoing antidepressants 1
Dose-Response Considerations
Evidence suggests efficacy at doses as low as 0.2 mg/kg, with increasing response up to 0.5 mg/kg. 3 Importantly, doses above 0.5 mg/kg do not demonstrate additional benefit and may increase adverse effects. 3 Alternative dosing formulas based on lean body mass or ideal body weight tend to result in underdosing and should be avoided. 5
Intranasal Esketamine Dosing
- Optimal dose range: 56-84 mg administered twice weekly 1, 3
- Lower doses: 28 mg shows inferior efficacy 3
- Administration requirements: Must be given in certified healthcare settings with mandatory 2-hour post-treatment monitoring due to REMS requirements 1
Clinical Context and Efficacy Timeline
Rapid Onset
Ketamine produces significant improvement in depressive symptoms within 24 hours of administration, with effects persisting at 3-4 day follow-up. 1 One study demonstrated dramatic reduction in depression scores (35.16 ± 8.13 to 14.90 ± 10.09) just one hour post-infusion. 2
Monotherapy vs. Adjunctive Use
When ketamine is used as monotherapy, benefits do not persist significantly beyond 7 days. 1 However, when added to ongoing antidepressant treatment, significant improvements extend to 7 days in treatment-resistant depression. 1
Suicidal Ideation
Ketamine infusions provide adjunctive short-term reduction in suicidal ideation in patients with MDD and active suicidal thoughts. 1 The 0.5 mg/kg dose shows rapid reduction in suicidal ideation scores (6.74 ± 6.67 to 0.42 ± 1.52 within one hour). 2
Critical Safety Considerations
Administration Requirements
- Must be administered by physicians experienced in general anesthesia and airway management 4
- Continuous vital sign monitoring is mandatory 4
- Emergency airway equipment must be immediately available 4
- The 100 mg/mL concentration must be diluted before IV use 4
Common Adverse Effects
Patients frequently experience increased heart rate, headache, dizziness, and dissociative symptoms. 2 These are generally mild to moderate and self-limited. 6
Long-term Safety Concerns
Chronic ketamine use has been associated with genitourinary pain and bladder dysfunction. 4 Consider cessation if genitourinary symptoms develop. 4 Long-term efficacy and safety data beyond 7 days remain limited for IV ketamine. 1
Abuse Potential
Ketamine carries risk of dependence and misuse. 7, 8 One case report documented ketamine misuse developing weeks after therapeutic administration. 9 This necessitates careful patient selection and monitoring.
Important Caveats
Contradictory Evidence
A recent 2025 randomized trial (KARMA-Dep 2) found no significant difference between serial ketamine infusions (0.5 mg/kg) and midazolam control in hospitalized patients receiving usual psychiatric care. 10 This suggests placebo effects and clinical attention may play substantial roles, though the study was limited to inpatient settings where baseline care is intensive.
Manic Switch Risk
Despite theoretical concerns in bipolar depression, studies show no increased risk of manic switches with ketamine at 0.8 mg/kg dosing. 6 Internal tension, sleep disturbance, and suicidal ideation improved without symptom worsening. 6
Patient Counseling
Advise patients not to drive or operate machinery for 24 hours post-treatment due to residual anesthetic effects. 4